CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Short Interest Down 46.7% in February

CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) saw a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 40,001 shares, a decline of 46.7% from the January 29th total of 74,980 shares. Based on an average trading volume of 2,958,451 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 2,958,451 shares, the short-interest ratio is currently 0.0 days.

CNBX Pharmaceuticals Stock Performance

Shares of OTCMKTS CNBX remained flat at $0.00 during trading hours on Friday. The stock had a trading volume of 175,033 shares, compared to its average volume of 21,213,670. CNBX Pharmaceuticals has a one year low of $0.00 and a one year high of $0.01.

CNBX Pharmaceuticals Company Profile

CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.

Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes.